Levosimendan Kalceks (Levosimendan)

• Levosimendan is used in the management of severe cardiac conditions where inotropic support and vasodilation are required.
• Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
• Cardiogenic shock: provides rapid inotropic support and reduces systemic vascular resistance.
• Severe low‑output heart failure: enhances myocardial contractility while maintaining coronary perfusion.

• Levosimendan increases myocardial contractility by binding to troponin C and sensitizing it to calcium, without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing afterload, which together improve cardiac output in heart failure patients.

Levosimendan may cause a range of adverse reactions, most of which are related to its cardiovascular and systemic actions.

Common Side Effects

• Hypotension: reduction in blood pressure, especially after rapid infusion.
• Headache: mild to moderate intensity, often transient.
• Nausea: occasional gastrointestinal upset.
• Tachycardia: increased heart rate due to inotropic effect.
• Arrhythmia: premature beats or mild rhythm disturbances.

Serious or Rare Side Effects

• Severe hypotension: may require vasopressor support.
• Ventricular arrhythmias: potentially life‑threatening rhythm disorders.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Allergic reactions: rash, pruritus, or anaphylaxis in rare cases.

When using Levosimendan, clinicians should consider several safety measures to minimize risk.

• Cardiac monitoring: continuous ECG and blood pressure monitoring during infusion.
• Renal impairment: adjust therapy and monitor renal function closely.
• Hepatic dysfunction: use with caution in patients with severe liver disease.
• Concomitant vasodilators: avoid or reduce dose to prevent excessive hypotension.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines that affect cardiovascular tone or metabolism.

Major Interactions (Avoid)

• Strong vasodilators (e.g., nitroglycerin): may cause profound hypotension.
• Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.
• Potent CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic effect.
• Diuretics: can exacerbate volume depletion and hypotension.
• ACE inhibitors or ARBs: additive blood‑pressure lowering effect.
• Calcium channel blockers: may influence vascular response.
• Moderate CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.